NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Investors are keeping a close eye on Vertex as the PDUFA date approaches, with the potential approval of suzetrigine marking ...
In a recent filing with the Securities and Exchange Commission, Vertex (NASDAQ:VRTX), Inc. (NASDAQ:VERX) disclosed that the ITEM SECOND IRR. TRUST FBO KYLE R. WESTPHAL, a significant shareholder, ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56 ... and the technology-dominated Nasdaq saw a decrease of 1.63%. Shares of the drugmaker witnessed a loss of 11.21% ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
This article summarizes the most significant insider buying and selling activities for US stocks reported on Thursday, ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback